Browse the corpus

Fexofenadine, a second-generation antihistamine, is a metabolite of terfenadine. The US Food and Drug Administration (FDA) approved fexofenadine to treat seasonal allergic rhinitis and chronic idiopathic urticaria. Fexofenadine is approved for use in both children and adults. Children may be eligible for treatment starting at 6 months or older, depending on the specific indications. Fexofenadine acts by selectively antagonizing H1 receptors on cell surfaces across various organ systems, thereby affecting inflammatory mediators. As a second-generation antihistamine, fexofenadine exhibits reduced affinity for cholinergic and α-adrenergic receptors, which results in minimal anticholinergic effects. This drug also demonstrates high specificity for H1 receptors and lacks anticholinergic activity. This activity provides information about fexofenadine, including its indications, mechanism of action, administration, adverse event profile, contraindications, and other critical factors such as monitoring, drug interactions, and clinical toxicology. This activity also aims to enhance the competence of interprofessional healthcare providers involved in treating patients with allergic rhinitis and chronic urticaria by providing them with the necessary skills to improve patient care. Objectives: Identify appropriate indications for fexofenadine therapy in patients with allergic rhinitis and chronic urticaria. Implement evidence-based guidelines for dosage and administration of fexofenadine in pediatric and adult populations based on patient age, severity of symptoms, and comorbidities. Assess patient response to fexofenadine therapy through regular monitoring of symptom improvement and adverse effects. Collaborate with other healthcare professionals to manage allergic rhinitis and chronic urticaria and comprehensively address patient concerns to optimize fexofenadine therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Fexofenadine, a metabolite of terfenadine, is associated with cardiotoxic effects. Terfenadine, when taken in high doses or with certain medications like ketoconazole, blocks cardiac potassium channels, resulting in prolonged QT intervals, which can lead to fatal arrhythmias. Following FDA guidelines, fexofenadine has replaced terfenadine in the United States due to its lack of potassium channel blockade. Multiple studies have confirmed that fexofenadine does not induce arrhythmias or significantly prolong QT intervals.[42] Despite the findings of these studies, some case reports have suggested a potential association between fexofenadine and QT-interval elongation and ventricular arrhythmia. Concurrent use of fexofenadine with hepatic CYP3A4 blockers, such as erythromycin and ketoconazole, may elevate blood concentration levels. In contrast, combined use with drugs such as rifampin and troglitazone can decrease concentration levels. These effects are likely attributed to interactions between these compounds and the P-gp transporter, which facilitates the removal of fexofenadine from the bloodstream.[45] Management of Overdose No specific antidote exists for fexofenadine overdose. Therefore, treatment in the event of an overdose primarily involves supportive measures. If an overdose is suspected, it is recommended to contact the poison control center or consult with a medical toxicologist, particularly if exposure to multiple substances is suspected.[46]

Fexofenadine is a commonly prescribed medication for seasonal allergic rhinitis and chronic urticaria. In addition, it is important to exercise caution when initiating any new medication without a prescription. Patients should engage in discussions with their primary care clinicians and pharmacists regarding fexofenadine to understand potential adverse effects, recommended dosing, and potential interactions with commonly consumed items such as fruit juices. Clinicians should also ensure that patients receive the appropriate adjusted dosage of fexofenadine. Immunologists should be consulted for cases of refractory urticaria or allergic rhinitis. Nurses should verify the dosage of fexofenadine at each visit and periodically reassess patients' conditions. Pharmacists should conduct thorough checks for drug interactions and perform medication reconciliation while counseling patients. In the event of fexofenadine overdose, critical care clinicians and medical toxicologists should be consulted. If the overdose is determined to be intentional, the patient should be promptly referred to a psychiatrist for further evaluation and management. Collaborative efforts and coordination among the interprofessional healthcare team, comprising clinicians, specialists such as immunologists, nurses, and pharmacists, are critical in improving patient outcomes related to fexofenadine therapy. As advocated by the European Academy of Allergy and Clinical Immunology, integrated care involving clinicians, specialists, nurses, dietitians, psychologists, and pharmacists can significantly enhance patient-centered care for allergic disorders in community settings.[47]